MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 20, 2006; DOI: 10.1124/mol.106.024125


0026-895X/06/7003-1062-1070$20.00
Mol Pharmacol 70:1062-1070, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.024125v1
70/3/1062    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anderson, G. R.
Right arrow Articles by Quattrochi, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderson, G. R.
Right arrow Articles by Quattrochi, L. C.

Regulation of the CYP1A1 Gene by 2,3,7,8-Tetrachlorodibenzo-p-dioxin but Not by beta-Naphthoflavone or 3-Methylcholanthrene Is Altered in Hepatitis C Virus Replicon-Expressing Cells

Garret R. Anderson, Aliya Hasan, Hao Yin, Ishtiaq Qadri, and Linda C. Quattrochi

Department of Medicine (G.R.A., A.H., L.C.Q.), Department of Pediatrics (I.Q.), School of Medicine, and Department of Pharmaceutical Sciences, School of Pharmacy (H.Y.), University of Colorado at Denver and Health Sciences Center, Denver, Colorado

Exposure to hepatitis C virus (HCV) can lead to the development of cirrhosis and hepatocellular carcinoma. To examine the effects of long-term HCV infection on hepatic cytochrome P450 1A1 (CYP1A1) expression and function, we used a human hepatoma cell line expressing the HCV subgenomic replicon (Huh.8) to evaluate CYP1A1 induction by the aryl hydrocarbon receptor (AhR) ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). In this study, we demonstrate that the induction of CYP1A1 expression in Huh.8 cells by TCDD but not by beta-naphthoflavone or 3-methylcholanthrene was significantly diminished. TCDD exposure of Huh.8 cells resulted in greater than 55% suppression of CYP1A1 transcription compared with the parent cell line Huh7, whereas protein levels and enzyme activities were further diminished. Suppression of CYP1A1 mRNA expression in TCDD-treated Huh.8 cells was partially reversed after pretreatment with the antioxidants N-acetylcysteine and nordihydroguaiaretic acid, suggesting a role for oxidative stress. Induced CYP1A1 message, protein, and enzyme activity were partially restored in an Huh7 cell line expressing the HCV replicon containing a deletion in the nonstructural protein NS5A. Furthermore, adenoviral expression of NS5A in Huh7 partially suppressed TCDD-induced CYP1A1 protein and enzyme activity, implicating this protein in the mechanism of suppression. These findings demonstrate that TCDD-mediated AhR signaling is impaired in hepatocytes in which HCV is present and that NS5A alone or in the presence of other nonstructural proteins of the subgenomic replicon is in part responsible.


Received for publication March 6, 2006.

Accepted for publication June 20, 2006.

Address correspondence to: Dr. Linda C. Quattrochi, Department of Medicine, University of Colorado at Denver and Health Sciences Center, 4200 E. 9th Avenue, Denver, CO 80262. E-mail: Linda.Quattrochi{at}UCHSC.edu




This article has been cited by other articles:


Home page
Toxicol SciHome page
M. Chopra, A. M. Dharmarajan, G. Meiss, and D. Schrenk
Inhibition of UV-C Light-Induced Apoptosis in Liver Cells by 2,3,7,8-Tetrachlorodibenzo-p-Dioxin
Toxicol. Sci., September 1, 2009; 111(1): 49 - 63.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics